ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Optimizing the Immunogenicity and Immunomodulatory Properties of MSC for Cellular Therapy.

S. de Witte,1 M. Franquesa,1 T. Strini,1 S. Korevaar,1 F. Luk,1 S. Elliman,2 P. Newsome,3 M. Gargesha,4 D. Roy,4 A. Merino,1 C. Baan,1 M. Hoogduijn.1

1ErasmusMC, Rotterdam, Netherlands
2Orbsen Therapeutics, Galway, Ireland
3University of Birmingham, Birmingham, United Kingdom
4Bioinvision, Mayfield Village.

Meeting: 2016 American Transplant Congress

Abstract number: D47

Keywords: Immune deviation, Immunogenicity, Inflammation, Stem cells

Session Information

Session Name: Poster Session D: Chimerism/Stem Cells, Cellular/Islet Transplantation, Innate Immunity, Chronic Rejection

Session Type: Poster Session

Date: Tuesday, June 14, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Mesenchymal stromal cells (MSC) are candidates for immunotherapy after transplantation. MSC have shown to be immunomodulatory and low immunogenic, which is favorable for cellular therapy applicability, but there is evidence that MSC are more immunogenic than previously thought. Also, improving their immunomodulation would be useful. This study aims to optimize MSC by making them better immunomodulators and less immunogenic. Umbilical cord-derived MSC were treated for 3 days under various conditions, i.e. with pro/antiinflammatory cytokines, vitamins and serum-deprivation. Their immunogenicity and immunosuppressive capacity were examined by geneexpression analysis, surfacemarker expressions, IDOactivity and inhibition of Tcell proliferation. Next, susceptibility to NKlysis was investigated. Furthermore, treatment of liver inflammation and MSC survival was examined in a CCL4-induced liverdisease mousemodel. Results showed increased immunomodulatory capacity of MSC after IFNγ, IFNβ and TGFβ treatment. IFNγtreated MSC were the most potent inhibitors of Tcell proliferation as well as their IFNγ production. Furthermore, increased HLA I and II, were observed in IFNγ, IFNβ, vitB6 and Starv+VitB6treated MSC. These MSC were protected against NKlysis, which correlate to increased HLA I. In addition, TGFβMSC were protected against NKlysis even though HLA levels remained unchanged. Table 1 displays effects of the most prominent factors on immunogenicity and immunomodulatory capacity. In vivo, TGFβMSC improved persistence after infusion while clearance of Starv, VitB6 and Starv+VitB6treated MSC was accelerated compared to untreated MSC. Nonetheless, liverfunction showed a trend of improvement after administration of TGFβ and Starvtreated MSC. These data show versatility of MSC to culture conditions and possibility of optimizing MSC into less immunogenic cells with improved immunomodulatory properties, which is important for further development of MSC for immunotherapy.

CITATION INFORMATION: de Witte S, Franquesa M, Strini T, Korevaar S, Luk F, Elliman S, Newsome P, Gargesha M, Roy D, Merino A, Baan C, Hoogduijn M. Optimizing the Immunogenicity and Immunomodulatory Properties of MSC for Cellular Therapy. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Witte Sde, Franquesa M, Strini T, Korevaar S, Luk F, Elliman S, Newsome P, Gargesha M, Roy D, Merino A, Baan C, Hoogduijn M. Optimizing the Immunogenicity and Immunomodulatory Properties of MSC for Cellular Therapy. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/optimizing-the-immunogenicity-and-immunomodulatory-properties-of-msc-for-cellular-therapy/. Accessed May 8, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences